A phase I-II, open-label study of RAD001 [everolimus] in combination with Gleevec [imatinib; ST 1571] in refractory/resistant gastrointestinal stromal tumors.

Next Previous
Trial Profile

A phase I-II, open-label study of RAD001 [everolimus] in combination with Gleevec [imatinib; ST 1571] in refractory/resistant gastrointestinal stromal tumors.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2016

At a glance

  • Drugs Everolimus (Primary) ; Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

    • Most Recent Events

    • 31 May 2012 Additional locations identified as reported by ClinicalTrials.gov.
    • 11 Jan 2011 Primary endpoint identified as (Pharmacokinetic-parameters, Objective-clinical-response) as reported by ClinicalTrials.gov.
    • 11 Jan 2011 Actual initiation date (Nov 2002) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top